171 related articles for article (PubMed ID: 21867844)
1. Low-density lipoprotein lowering does not improve calf muscle perfusion, energetics, or exercise performance in peripheral arterial disease.
West AM; Anderson JD; Epstein FH; Meyer CH; Wang H; Hagspiel KD; Berr SS; Harthun NL; Weltman AL; Dimaria JM; Hunter JR; Christopher JM; Kramer CM
J Am Coll Cardiol; 2011 Aug; 58(10):1068-76. PubMed ID: 21867844
[TBL] [Abstract][Full Text] [Related]
2. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline.
West AM; Anderson JD; Meyer CH; Epstein FH; Wang H; Hagspiel KD; Berr SS; Harthun NL; DiMaria JM; Hunter JR; Christopher JM; Chew JD; Winberry GB; Kramer CM
Atherosclerosis; 2011 Sep; 218(1):156-62. PubMed ID: 21570685
[TBL] [Abstract][Full Text] [Related]
3. Percutaneous intervention in peripheral artery disease improves calf muscle phosphocreatine recovery kinetics: a pilot study.
West AM; Anderson JD; Epstein FH; Meyer CH; Hagspiel KD; Berr SS; Harthun NL; Weltman AL; Annex BH; Kramer CM
Vasc Med; 2012 Feb; 17(1):3-9. PubMed ID: 22363013
[TBL] [Abstract][Full Text] [Related]
4. Multifactorial determinants of functional capacity in peripheral arterial disease: uncoupling of calf muscle perfusion and metabolism.
Anderson JD; Epstein FH; Meyer CH; Hagspiel KD; Wang H; Berr SS; Harthun NL; Weltman A; Dimaria JM; West AM; Kramer CM
J Am Coll Cardiol; 2009 Aug; 54(7):628-35. PubMed ID: 19660694
[TBL] [Abstract][Full Text] [Related]
5. Arterial spin labeling MR imaging reproducibly measures peak-exercise calf muscle perfusion: a study in patients with peripheral arterial disease and healthy volunteers.
Pollak AW; Meyer CH; Epstein FH; Jiji RS; Hunter JR; Dimaria JM; Christopher JM; Kramer CM
JACC Cardiovasc Imaging; 2012 Dec; 5(12):1224-30. PubMed ID: 23236972
[TBL] [Abstract][Full Text] [Related]
6. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
7. High-energy phosphate metabolism during incremental calf exercise in patients with unilaterally symptomatic peripheral arterial disease measured by phosphor 31 magnetic resonance spectroscopy.
Greiner A; Esterhammer R; Messner H; Biebl M; Mühlthaler H; Fraedrich G; Jaschke WR; Schocke MF
J Vasc Surg; 2006 May; 43(5):978-86. PubMed ID: 16678693
[TBL] [Abstract][Full Text] [Related]
8. Increasing doses of simvastatin versus combined ezetimibe/simvastatin: effect on circulating endothelial progenitor cells.
Pesaro AE; Serrano CV; Katz M; Marti L; Fernandes JL; Parra PR; Campos AH
J Cardiovasc Pharmacol Ther; 2013 Sep; 18(5):447-52. PubMed ID: 23739650
[TBL] [Abstract][Full Text] [Related]
9. The effect of simvastatin, ezetimibe and their combination on the lipid profile, arterial stiffness and inflammatory markers.
Efrati S; Averbukh M; Dishy V; Faygenzo M; Friedensohn L; Golik A
Eur J Clin Pharmacol; 2007 Feb; 63(2):113-21. PubMed ID: 17200833
[TBL] [Abstract][Full Text] [Related]
10. Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Blazing MA; Giugliano RP; Cannon CP; Musliner TA; Tershakovec AM; White JA; Reist C; McCagg A; Braunwald E; Califf RM
Am Heart J; 2014 Aug; 168(2):205-12.e1. PubMed ID: 25066560
[TBL] [Abstract][Full Text] [Related]
11. Achievement of specified low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol apolipoprotein B, and high-sensitivity C-reactive protein levels with ezetimibe/simvastatin or atorvastatin in metabolic syndrome patients with and without atherosclerotic vascular disease (from the VYMET study).
Robinson JG; Ballantyne CM; Hsueh W; Rosen J; Lin J; Shah A; Lowe RS; Hanson ME; Tershakovec AM
J Clin Lipidol; 2011; 5(6):474-82. PubMed ID: 22108151
[TBL] [Abstract][Full Text] [Related]
12. Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Oyama K; Giugliano RP; Blazing MA; Park JG; Tershakovec AM; Sabatine MS; Cannon CP; Braunwald E
J Am Coll Cardiol; 2021 Oct; 78(15):1499-1507. PubMed ID: 34620406
[TBL] [Abstract][Full Text] [Related]
13. Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.
Farnier M; Taggart W; Dong Q; Lin J; Shah A; Brudi P
J Clin Lipidol; 2011; 5(3):179-187. PubMed ID: 21600523
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
Jimenez JG; Rosen JB; Pirags V; Massaad R; Hanson ME; Brudi P; Triscari J
Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
[TBL] [Abstract][Full Text] [Related]
15. Co-administration of ezetimibe and simvastatin in acute myocardial infarction.
Chenot F; Montant PF; Marcovitch O; Blaimont M; de Meester A; Descamps OS
Eur J Clin Invest; 2007 May; 37(5):357-63. PubMed ID: 17461981
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Cannon CP; Blazing MA; Giugliano RP; McCagg A; White JA; Theroux P; Darius H; Lewis BS; Ophuis TO; Jukema JW; De Ferrari GM; Ruzyllo W; De Lucca P; Im K; Bohula EA; Reist C; Wiviott SD; Tershakovec AM; Musliner TA; Braunwald E; Califf RM;
N Engl J Med; 2015 Jun; 372(25):2387-97. PubMed ID: 26039521
[TBL] [Abstract][Full Text] [Related]
17. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Rosen JB; Jimenez JG; Pirags V; Vides H; Massaad R; Hanson ME; Brudi P; Triscari J
Lipids Health Dis; 2013 Jul; 12():103. PubMed ID: 23866306
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
19. Effects of simvastatin and ezetimibe in lowering low-density lipoprotein cholesterol in subjects with type 1 and type 2 diabetes mellitus.
Ciriacks K; Coly G; Krishnaswami S; Patel SB; Kidambi S
Metab Syndr Relat Disord; 2015 Mar; 13(2):84-90. PubMed ID: 25490061
[TBL] [Abstract][Full Text] [Related]
20. Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease.
Sharp Collaborative Group
Am Heart J; 2010 Nov; 160(5):785-794.e10. PubMed ID: 21095263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
